Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

UNITAID - Financed Project to Increase Access to New HIV Monitoring Technology

Published: Thursday, February 14, 2013
Last Updated: Wednesday, February 13, 2013
Bookmark and Share
Agreement signed with FEI to improve HIV monitoring through affordable access to viral load testing for HIV patients and early infant diagnosis in resource-limited settings.

UNITAID and France Expertise Internationale (FEI) have signed a US$ 2.4 million agreement to implement the “OPP-ERA” project which will stimulate the market entry of new manufacturers and suppliers of HIV Viral Load Test (VLT) technologies, bringing an innovative solution to meet the HIV monitoring and diagnostics needs in resource-limited settings.

OPP-ERA - OPP standing for Open Polyvalent Platforms - is an innovative system to detect HIV viral load, which enables machines and reagents coming from different manufacturers and suppliers to be used together.

This diagnostic system is flexible, rapid, and easy to use, with appropriate-sized machines for peripheral settings.

The OPP system can be used not only for HIV viral load testing and early infant diagnosis, but also for other infectious agents.

This initiative aims to bring the prices of these tests down.

OPP-ERA will focus on viral load testing for adults and early infant diagnosis of HIV. Viral load testing is crucial to determine when patients need to switch treatments.

Currently, less than 10% of HIV patients in low-income settings have access to viral load tests as they are expensive and usually only available in the central laboratories of capitals.

Early infant diagnosis is essential for young infants born to mothers living with HIV. In 2011 alone, 230,000 children died of AIDS-related causes, most before the age of two. These deaths could have been avoided by making an accurate diagnosis followed by adapted treatment in the first weeks of life.

UNITAID will finance OPP-ERA for an initial pilot stage in 4 countries: Burundi, Cameroon, Côte d’Ivoire, and Guinea. The project will be implemented by a consortium of partners led by FEI, comprising the French National Agency for Research on AIDS and Viral Hepatitis (ANRS), the Network for Therapeutic Solidarity in Hospitals (ESTHER), SIDACTION and Therapeutic Solidarity and Initiatives against AIDS (SOLTHIS).

FEI is a French governmental agency for international cooperation and development under the supervision of the French Ministry of Foreign and European Affairs.

OPP-ERA is a key part of UNITAID’s investment to bring vital HIV monitoring and testing to remote communities. “The UNITAID Executive Board has approved grants to the Clinton Health Access Initiative, UNICEF, Médecins Sans Frontières and FEI to introduce new diagnostics. OPP-ERA completely fits into UNITAID’s approach to provide a comprehensive response to affordable diagnostic tools in countries in need”, said Dr Denis Broun, Executive Director of UNITAID.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Drug - Gene 'One-Two' Punch Against Cancer
Researchers identify gene-drug combinations that, together, target and kill cancer cells while not targeting healthy cells.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
72% Rise in Metastatic Prostate Cancer
Over the 2003-2013 period metastatic cancer has increased by an average of 72%, this could be caused by lax screening, more aggressive disease or both.
Lab-Tested Diagnosis Needed When Treating Persistent Diarrhea
New PCR multiplex method makes lab testing more effective.
Biomarker for Multiple Sclerosis Detection Discovered
Winthrop-University Hospital researchers discover biomarker for multiple sclerosis detection.
Scientists Link Bipolar Disorder to Unexpected Brain Region
Researchers from The Scripps Research Institute have found that gene within the brain’s striatum could be linked to biopolar disorder.
Liquid Biopsies: DNA Size Matters
Study finds circulating tumour DNA can be distinguished from healthy DNA through fragment size identification.
Accessing Metabolic Information with Mass Spec
Scientists at the Helmholtz Zentrum München have developed a new mass spectrometry imaging method which, for the first time, makes it possible to analyze hundreds of metabolites in fixed tissue samples.
Zika Epidemic Likely to End Within Three Years
A team of scientists has predicted that the current Zika epidemic is likely to end within three years because there will be too few people left to infect.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!